Skip to content
Life Sciences Series C Founded 2009

RareCyte

Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging…

📍 Seattle, United States · Genomics,

Funding snapshot

Last roundSeries C
Amount$658K
Date20 May 2025
Total raised$114M
Team size61

About

Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis). Founded in 2009, headquartered in Seattle, United States. RareCyte operates in the Genomics, Life Sciences Platforms and Tools, Clinical Genomics sectors. The company focuses on Detection and Quantification, NGS Reagents. The company has raised $114.3M in Series C funding. Notable investors include Health Quest Capital, 5AM Ventures, Telegraph Hill Partners, F-Prime Capital, Arboretum Ventures, Agilent, among others.

Business model

Genomics > Enabling Technologies > Kits and Reagents > Detection and Quantification,

Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > NGS Reagents

Institutional investors

Health Quest Capital 5AM Ventures Telegraph Hill Partners F-Prime Capital Arboretum Ventures Agilent The Forest Road Company GKCC Sheatree Capital Logos HHS GT Healthcare Capital Partners Ron Seubert

Latest coverage

No articles yet.

Raising like RareCyte?

Analyze your pitch deck before your next raise.

Analyze My Deck →